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Abstract
Background: Acute lower respiratory tract infections (ALRTIs) account for most antibiotics prescribed 
in primary care despite lack of efficacy, partly due to clinician uncertainty about aetiology and patient 
concerns about illness course. Nucleic acid amplification tests could assist antibiotic targeting.
Methods: In this prospective cohort study, 645 patients presenting to primary care with acute 
cough and suspected ALRTI, provided throat swabs at baseline. These were tested for respiratory 
pathogens by real-time polymerase chain reaction and classified as having a respiratory virus, 
bacteria, both or neither. Three hundred fifty-four participants scored the symptoms severity daily 
for 1 week in a diary (0 = absent to 4 = severe problem).
Results: Organisms were identified in 346/645 (53.6%) participants. There were differences in 
the prevalence of seven symptoms between the organism groups at baseline. Those with a virus 
alone, and those with both virus and bacteria, had higher average severity scores of all symptoms 
combined during the week of follow-up than those in whom no organisms were detected [adjusted 
mean differences 0.204 (95% confidence interval 0.010 to 0.398) and 0.348 (0.098 to 0.598), 
respectively]. There were no differences in the duration of symptoms rated as moderate or severe 
between organism groups.
Conclusions: Differences in presenting symptoms and symptoms severity can be identified 
between patients with viruses and bacteria identified on throat swabs. The magnitude of these 
differences is unlikely to influence management. Most patients had mild symptoms at 7  days 
regardless of aetiology, which could inform patients about likely symptom duration.
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Introduction
Acute respiratory tract infections are the most common infection 
presenting to primary care (1) with between 40% and 70% of 
adults suffering at least one episode annually (2). They are the most 
common reason for antibiotic prescriptions in primary care (3) des-
pite the majority having a viral aetiology (4). Up to 70% presenting 
with cough and bronchitis, will receive an antibiotic prescription (5, 
6). Yet, the Cochrane meta-analysis of 17 randomized controlled 
trials, suggest little benefit from antibiotics in these conditions (7).
The factors influencing the prescription of an antibiotic are com-
plex (8, 9). Among the factors clinicians cite is the uncertainty in 
distinguishing bacterial from viral infections (10, 11), particularly in 
‘middle cases’ (12), while the perceived severity of illness and the im-
pact on social roles, influence patients’ decisions to consult (13, 14).
Clinical findings traditionally used to guide antibiotic prescribing 
in primary care correlate poorly with outcome (15–17), although 
more complex clinical scores can identify those at risk of adverse 
outcome (18). The use of point of care tests (POCTs), such as 
C-Reactive Protein, can distinguish more patients as low risk and 
reduces antibiotic prescriptions (19). Nucleic acid amplification 
tests (NAATs) that identify infecting organisms have the potential 
to increase the diagnostic accuracy, inform prognosis and guide anti-
microbial therapy. Therefore, the development of NAATs as POCTs 
could influence management decisions (20).
Our aims were to describe differences in clinical presentation and 
clinical course between patients with viruses or bacteria detected 
using real-time polymerase chain reaction (PCR) on throat swabs. 
Identifying features that make viral infections more likely could help 
support GPs to avoid antibiotic prescriptions and provide an evi-
dence base for the use of POCTs to improve therapeutic decision 
making and provide prognostic information to inform patients of 
the likely duration of their symptoms.
Methods
Study population
The participants included in this investigation are a subcohort (3C 
Plus) of the prospective Cough Complication Cohort (3C) study. 
Thirteen practices in the south of England, which were already 
participating in the 3C study, agreed to take part in 3C Plus. The 
methods for recruitment and data collection are similar to those in 
the parent cohort (21, 22). Briefly, the participants were patients 
aged 16 years and older who presented to UK general practices with 
a first episode of acute cough of less than 28 days duration between 
April and December 2013.
At baseline, participants answered questionnaires and provided 
data on their sociodemographic and medical history. Participants 
underwent a clinical assessment including severity (mild, moderate, 
or severe) of their symptoms and had vital signs measured.
Outcomes
At baseline, the participants were provided with a symptom diary in 
which they were asked to record the severity of their symptoms from 
Day 0 (baseline) until Day 7. Symptom severity was rated as 0 (not 
present), 1 (present, no problem), 2 (present, mild problem), 3 (pre-
sent, moderate problem), and 4 (present, severe problem). The par-
ticipants also recorded their temperature at the same time each day, 
but at least 2 hours after taking any antipyretic for the 7 days after 
clinical examination using disposable thermometers (TempaDotTM) 
provided to them.
Using the participants’ reported symptom severity, we created 
two outcomes as defined elsewhere (23) to allow comparability with 
previous studies: (i) average symptom score severity between Days 2 
to 4 inclusive, and (ii) longest duration of any symptom rated by the 
participants as moderate or severe during the 7 days after consult-
ation. For (i), we took the average severity for each symptom in Days 
2 to 4, and then took the average of these scores across all symptoms. 
Severity scores that were missing on a particular day were ignored 
in the calculations. For (ii), we censored participants who reported 
moderate or severe symptoms on their last day of follow-up. The 
number of patients with missing outcome data was greater for out-
come 1 than for outcome 2, due to some patients having reported 
their symptoms only on Day 1.
Microbiological sampling
Clinicians were instructed on taking oropharyngeal swabs using a 
nylon-flocked swab by gently swabbing between the tonsullar pillars 
and the tonsules on both sides of the throat. Swabs were transported 
to the Nuffield Department of Medicine Laboratory at the Oxford 
University Hospitals NHS Foundation Trust Hospital in 2 ml eNAT 
Transport and Preservation medium (COPAN Italia), where they 
were stored at −80°C until transport to the South West Regional 
Laboratory, PHE, Bristol. The study was approved by Oxford 
Research Ethics Committee A (09/H0604/67).
Microbe identification and grouping
Identification of 10 viruses and 11 bacteria (Supplementary Material 
1) from throat swabs was done by real-time PCR using Taqman Low 
Density Array cards as described elsewhere (24). We divided the par-
ticipants into 4 groups depending on the detection of organisms: (i) 
no organisms detected, (ii) ≥1 virus, but no bacteria (iii) ≥1 bacteria, 
but no viruses, or (iv) ≥1 virus and ≥1 bacteria. In the primary ana-
lysis, we used the same classification for bacterial pathogens as the 
GRACE study (4). In brief, this means six of the bacteria detected 
were not considered as pathogenic, and therefore not used to guide 
categorization of patients into groups (iii and iv). In a sensitivity 
analysis, we made no assumptions on whether bacteria were likely to 
have a role in pathogenicity or asymptomatic carriage and included 
all bacteria identified.
Statistical analyses
Details on sample size calculation are provided in Supplementary 
Material 2.
We described the baseline characteristics across the four groups 
using means and SDs for continuous variables, and number and per-
centages for categorical variables. We used analysis of variance and 
Key Messages
• At baseline, the prevalence of seven symptoms differed between organisms groups
• Those with a virus detected had higher severity of symptoms during follow-up
• Most patients had mild symptoms after 1 week regardless of aetiology
2 Family Practice, 2019, Vol. XX, No. XX
D
ow
nloaded from
 https://academ
ic.oup.com
/fam
pra/advance-article-abstract/doi/10.1093/fam
pra/cm
z093/5679613 by U
niversity of Bristol Library user on 08 January 2020
chi-squared tests to assess dependence between the groups and con-
tinuous and categorical baseline variables, respectively.
We used linear regression models to estimate mean differences 
(MD) and 95% confidence intervals (CI) in outcomes 1 and 2 among 
the four groups, with the group with no organisms as reference. We 
used both unadjusted models and models adjusting for age, reported 
duration of illness before presentation, and antibiotic prescription.
We also analysed differences in the medians for outcome 2 be-
tween groups with Kaplan-Meier curves and the log-rank test using 
the R packages ‘survival’ and ‘survminer’ (25, 26). Cox proportional 
hazards regression was used to adjust for the same covariates as 
above. The proportional hazards assumption was tested and there 
was no evidence this assumption was violated.
We performed similar analyses to compare those with and 
without the most common organisms, that is, those present in more 
than 10% of the sample, adjusting additionally for co-infection with 
other viruses and/or bacteria.
We plotted means and 95% CIs of symptom severity score from 
Day 1 to Day 7 by group, for all symptoms combined. Although the 
outcome measure averaged across all symptoms, to show the pos-
sible effect on specific symptoms we also showed these graphically 
without performing additional hypothesis tests.
All statistical tests were two-sided using a significance level of 
5% and we reported all outcome results with 95% CIs. Analyses 
were carried out using R (version 3.6.0) (27).
Results
Overall, 645 participants completed the baseline assessment and pro-
vided throat swab samples. Of these, 354 filled in the symptom diary 
over the 7 days after baseline inclusion (Supplementary Material 3). 
Those who completed the symptom diary were older and more likely 
to have received antibiotics, to have higher systolic blood pressure 
at presentation, lower pulse rate, lower oxygen saturation, less likely 
to smoke, and to report muscle aches. There were no differences in 
the distribution of completers and no completers across organism 
groups (Supplementary Material 4).
Table 1 shows the number of study participants in each of the 
four groups and the organisms identified in the throat swab. The 
largest group comprised those with no organisms detected (n = 299, 
46.4%), followed by those with viruses detected but no bacteria 
(n = 151, 23.4%), those with bacteria detected but no virus (n = 120, 
18.6%), and those with both viruses and bacteria (n = 75, 11.6%). 
Haemophilus influenzae was the commonest organism (n  =  166, 
25.7%), followed by Picornavirus group (n = 165, 25.6%). The fre-
quencies for the bacteria included in the sensitivity analyses across 
groups are shown in Supplementary Material 5.
The baseline characteristics of participants in the four groups 
are summarized in Table 2. Patients with no organisms detected 
were older and patients with both bacteria and viruses detected 
were younger. The reported duration of illness before clinical 
presentation was shorter for those with a viral infection alone, 
although the illness was not perceived as having worsened dif-
ferently between groups. Antibiotics were prescribed to 232 pa-
tients with no organism detected (77.6%), and to 117 patients 
with virus alone (77.5%), and to 83 patients with bacteria alone 
(69.2%). Smoking status did not vary across groups, but among 
past smokers, there were significant differences in years since ces-
sation between organism groups. Seven symptoms were reported 
more commonly in those with virus alone, than among those 
with bacteria alone or no infection. The same symptoms, except 
muscle aches, were also reported more commonly in those with 
both virus and bacteria combined, than among those with a bac-
teria or virus alone. There were no significant differences in vital 
signs across the four groups.
Symptom severity during follow-up
Compared to those without an organism, those with a viral infection 
alone (MD, 95% CI: 0.204, 0.010 to 0.398) and those with a com-
bined viral and bacterial infection (MD, 95% CI: 0.348, 0.098 to 
0.598) had higher symptom severity scores, while there was no dif-
ference in those with bacterial infection alone (MD, 95% CI: 0.192, 
-0.008 to 0.391) (Table 3). In the sensitivity analysis, we observed 
similar findings (Supplementary Material 6).
Table 1. Frequencies of organisms identified by PCR in the prospective Cough Complication Cohort (3C) Plus study 2013
 
Overall (n = 645) Organism group
None (n = 299) Viral (n = 151) Bacterial (n = 120) Both (n = 75)
Virus, n (%)      
 Picornavirusa 165 (25.6) - 105 (16.3) - 60 (9.3)
 Human parainfluenza virus 21 (3.3) - 19 (2.9) - 2 (0.3)
 Respiratory syncytial virus 20 (3.1) - 16 (2.5) - 4 (0.6)
 Influenza A 10 (1.5) - 6 (0.9) - 4 (0.6)
 Human coronavirus 9 (1.4) - 5 (0.8) - 4 (0.6)
 Human metapneumovirus 2 (0.3) - 1 (0.2) - 1 (0.2)
 Influenza B 1 (0.2) - 1 (0.2) - 0 (0.0)
 Adenovirus 1 (0.2) - 1 (0.2) - 0 (0.0)
 Bocavirus 0 (0.0) - 0 (0.0) - 0 (0.0)
 Parechovirus 0 (0.0) - 0 (0.0) - 0 (0.0)
Bacteria, n (%)      
 Haemophilus influenzae 166 (25.7) - - 98 (15.2) 68 (10.5)
 Streptococcus pneumoniae 24 (3.7) - - 11 (1.7) 13 (2.0)
 Bordetella pertussis 3 (0.5) - - 2 (0.3) 1 (0.2)
 Chlamydia pneumoniae 3 (0.5) - - 3 (0.5) 0 (0.0)
 Mycoplasma pneumoniae 2 (0.3) - - 2 (0.3) 0 (0.0)
aPicornavirus group combines organisms identified as either in Enterovirus genus or Rhinovirus species.
Microbiology of throat swabs and prognosis in patients with acute cough 3
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For organisms with a prevalence >10%, those with H. influenzae 
isolated (n = 88), compared to those without (n = 257), had higher 
severity scores (MD, 95% CI: 0.272, 0.103 to 0.442) but there was 
no difference in those with and without Picornavirus infections.
Figure 1 shows mean and 95% CI for the combined symptom 
severity score between Day 1 and Day 7 for all groups. Symptom 
severity appeared highest for those with both viral and bacterial 
infection combined, followed by those with a viral or bacterial in-
fection alone. Severity of symptoms appeared lowest for those with 
no infection. In the sensitivity analysis, the differences in symptom 
severity between groups were similar, but the difference between the 
viral and the no infection group was more evident (Supplementary 
Material 7).
Severity scores of selected symptoms are shown in Supplementary 
Material 8. Those with a viral infection alone, and combined viral 
and bacterial infection, appeared to have higher severity scores for 
wheeze and blocked nose throughout the 7  days and this differ-
ence declined progressively. The severity scores for the groups were 
similar for the symptoms of dry cough, chills, muscle aches, and tem-
perature. In the sensitivity analysis, similar patterns were observed, 
but the difference between the two groups with viral organisms 
and the group with no infection were more evident (Supplementary 
Material 9).
Duration of symptoms
After adjustment for age, antibiotic prescription, duration of illness, 
and co-infection, there were no differences detectable between 
groups (Table 4). In the sensitivity analysis, there were also no sig-
nificant differences in duration of symptoms between organism 
groups (Supplementary Material 10). There were no differences in 
duration of symptoms rated as moderate or severe between those 
with and without H. influenzae or Picornavirus organisms.
In analyses including censoring participants whose rating of 
symptoms was missing on the following day, there were no differ-
ences (P-value for comparing four groups  =  0.70) in the median 
(5–6 days) duration of symptoms rated by participants as moderate 
or severe (Supplementary Material 11), even after adjusting for 
confounders (Supplementary Material 12).
Discussion
Summary of principal findings
In primary care patients with acute cough, a potential pathogen 
could be detected in 53.6% of throat swabs and the prevalence of 
seven symptoms at presentation differed between organism groups. 
Symptom severity scores during follow-up were higher in those with 
a virus regardless of bacterial co-detection. However, there was no 
difference in the duration of symptoms rated as moderate or severe 
between organism groups. Adjusting for antibiotic prescription did 
not change these results. There were no differences in symptom se-
verity or duration between those with and without the commonest 
virus and bacteria. By Day 7, most patients rated their symptoms as 
mild or less, including those symptoms rated as most severe initially.
Strengths and weaknesses of the study
The recruitment of patients presenting with acute cough from rou-
tine consultations, using the same criteria as the 3C Study of more 
than 28,000 patients, was designed to make the study population 
widely generalizable. The diary response rate of only 54.8% was 
lower than for other studies of respiratory infection outcomes (14, 
16, 28). However, although those returning diaries were older and 
less likely to be current smokers, returning the symptoms diary was 
unrelated to the results of the microbiology of swabs (Supplementary 
Material 4). As diary data were available for a maximum of 7 days 
after initial presentation, around one-third of participants still had 
at least one moderate of severe symptom at the end of follow-up, 
and for these participants the time until all symptoms resolved was 
unknown.
The optimal site for sampling different organisms varies and 
increasing the number of sampling sites increases the detection rate 
(29). We took a pragmatic decision to use oropharyngeal swabs, 
which are associated with disease prognosis and antimicrobial use 
(30). Oropharyngeal swabs have also been used in studies on respira-
tory infections in children (24), have the advantage of being avail-
able in nearly all patients, and improve uptake with busy clinicians 
and patients (24). Therefore, they are of practical value as a future 
site for simple point of care testing.
Table 3. Symptom severity measured as the mean diary score for all symptoms during Days 2 to 4 after the baseline consultation in the 
prospective Cough Complication Cohort (3C) Plus study 2013
Predictor n Symptom severity Unadjusted Adjusteda
Mean (SD) MD (95% CI) MD (95% CI)
Organism group        
 None 161 1.23 (0.72) - Reference - Reference
 Viral 78 1.43 (0.66) 0.201 (0.008 to 0.393) 0.204 (0.010 to 0.398)
 Bacterial 68 1.40 (0.70) 0.170 (−0.032 to 0.371) 0.192 (−0.008 to 0.391)
 Both 38 1.63 (0.79) 0.392 (0.140 to 0.644) 0.348 (0.098 to 0.598)
Haemophilus influenzae     
 No 257 1.28 (0.70) - Reference - Reference
 Yes 88 1.58 (0.73) 0.295 (0.123 to 0.467) 0.272 (0.103 to 0.442)
Picornavirusb        
 No 263 1.32 (0.71) - Reference - Reference
 Yes 82 1.48 (0.74) 0.163 (−0.015 to 0.341) 0.116 (−0.062 to 0.293)
Numbers in bold denote statistical significance.
aAdjusted for age, antibiotic prescription and duration of illness. Analysis for specific organisms was also adjusted for viral co-infection for those with 
Haemophilus influenzae, and for bacterial co-infection for those with Picornavirus.
bPicornavirus group combines organisms identified as either in Enterovirus genus or Rhinovirus species.
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The study had sufficient power for comparison to patients where 
no bacteria or viruses were found but limited power for compari-
sons between groups where bacteria or viruses were found. For the 
primary analysis of diary data, we used a similar classification of 
bacteria as pathogens as the GRACE study (4) but including the 
full panel of bacteria in sensitivity analyses did not alter our con-
clusions. We had intended to investigate recovery for individual 
organisms with a prevalence >10%, but due to our limited sample 
size, we could only investigate Picornavirus and H. influenzae. Thus, 
our grouping of individual organisms into broader groups may have 
obscured potentially important relationships that only much larger 
studies would be powered to detect. In past smokers, we observed 
significant differences in time since smoking cessation between or-
ganism groups, but as this variable was not associated with out-
comes, we did not adjust for it in multivariable models.
Results in the context of other studies
Clinicians place great weight on clinical signs in their decision to 
prescribe antibiotics (31) and some signs, such as abnormal chest 
findings or discoloured sputum, are associated with antibiotic pre-
scriptions (32). However, clinical signs and clinician assessments are 
only modestly helpful for predicting pneumonia and the need for 
antibiotics (15, 33, 34). Our study is consistent with these findings: 
differences that were detectable between groups for seven symptoms 
were small and unlikely to be helpful to clinicians in differentiating 
viral from bacterial infections.
In the placebo arms of RCTs of antibiotics in acute bronchitis, 
the mean number of days feeling ill ranges from 3 to 18 days (7). 
and in a study of patients with more severe illness (most had chest 
signs and 13% pneumonia) who completed diaries, around 50% of 
patients describe themselves as being symptomatic 1  month after 
Table 4. Duration of symptoms rated by participants as moderate or severe after initial presentation (i.e. the last day on which a rating of 
moderate or severe was recorded in the diary for any symptom) in the prospective Cough Complication Cohort (3C) Plus study 2013
Predictor n Duration Unadjusted Adjusteda
Mean (SD) MD (95% CI) MD (95% CI)
Organism        
 None 162 4.40 (2.53) - Reference - Reference
 Viral 78 4.65 (2.23) 0.25 (−0.39 to 0.89) 0.17 (−0.48 to 0.82)
 Bacterial 69 4.55 (2.30) 0.15 (−0.52 to 0.82) 0.18 (−0.49 to 0.85)
 Both 38 5.00 (2.03) 0.60 (−0.24 to 1.44) 0.51 (−0.33 to 1.35)
Haemophilus influenzae      
 No 259 4.42 (2.42) - Reference - Reference
 Yes 88 4.94 (2.16) 0.52 (−0.05 to 1.09) 0.51 (−0.07 to 1.08)
Picornavirusb        
 No 265 4.53 (2.44) - Reference - Reference
 Yes 82 4.63 (2.14) 0.11 (−0.48 to 0.69) −0.02 (−0.62 to 0.58)
aAdjusted for age, antibiotic prescription, and duration of illness. Analysis for specific organisms was also adjusted for viral co-infection for those with 
Haemophilus influenzae, and for bacterial co-infection for those with Picornavirus.
bPicornavirus group combines organisms identified as either in Enterovirus genus or Rhinovirus species.
Figure 1. Mean and 95% CI severity scores for all symptoms combined from Day 1 to Day 7 across groups in the prospective Cough Complication Cohort (3C) 
Plus study 2013.
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ALRTI (35). In our study, the mean score for all symptoms declined 
over the 7 days and less than half described their symptoms as more 
than moderate. We used the mean symptom severity score on Days 
2 to 4 after presentation since this is the period when symptoms are 
rated as worse by patients (23) but, although there were differences 
between groups, these were small and unlikely to be meaningful to 
patients.
Nucleic acid amplification tests cannot distinguish between col-
onizing and causative organisms. In the GRACE study, viruses were 
found significantly more commonly in symptomatic illness and 
when these patients recovered (35), the same viruses were found at 
a similar prevalence to those in controls again (4). There have been 
similar findings in children (24). Although we did not include con-
trols or follow-up samples, seven symptoms were more common in 
patients with viral infections, regardless of whether they also had 
a bacterial infection, than in patients with a bacterial or no infec-
tion. Since neither the clinicians nor the patients were aware of the 
throat swab result at the time, it is unlikely bias accounted for these 
differences.
In our study, viruses alone were detected in 35.6% of patients, 
compared to 48.1% in GRACE. However, we did not include the 
peak period of influenza circulation (36), which would explain most 
of this difference. In 299 participants (46.4%), we could not de-
tect any respiratory viruses or pathogenic bacteria that we were 
investigating, which is similar to 41% of patients with ALRTI in 
the GRACE study in which no organism could be detected. Possible 
explanations include presentation of non-infective illnesses, such as 
cardiac conditions or malignancy (21), or false-negative results: al-
though the Taqman© assay is widely used and has high accuracy 
(37), it is estimated that the organisms responsible for between 12 
and 39% of lower respiratory infections are still to be identified (38).
Implications
Antibiotics confer little benefit in non-pneumonic ALRTI (23), but 
there is preliminary evidence from the GRACE study that patients 
with combined viral and bacterial infections could potentially benefit 
from antibiotics. This study provides further evidence that clinicians 
cannot easily differentiate on clinical grounds those who might be 
more likely to benefit and this is likely to contribute to the difficulty 
of reducing antibiotic prescribing. Larger data sets, including sam-
ples collected in different seasons, could establish whether grouping 
all viruses and bacteria together masks important relationships.
Conclusion
In primary care patients with ALRTI, differences in symptom preva-
lence at presentation and symptom severity score after consultation 
can be identified between patients with viruses and bacteria identi-
fied on throat swabs using real-time PCR. However, these differences 
are small, highlighting the difficulty facing clinicians, and unlikely to 
influence prescribing decisions for individual patients.
Supplementary material
Supplementary material is available at Family Practice online.
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